Evidence map›Paper›PMID 39897579›Full record

ArticleMolecular therapy. Nucleic acids2025

Glutamine missense suppressor transfer RNAs inhibit polyglutamine aggregation.

Rasangi Tennakoon, Teija M I Bily, Farah Hasan, Sunidhi Syal, Aaron Voigt, Tugce B Balci, Kyle S Hoffman, Patrick O'Donoghue

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Natural human tRNARNA (New York, N.Y.) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Rasangi TennakoonDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.
Teija M I BilyDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.
Farah HasanDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.
Sunidhi SyalDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.
Aaron VoigtDepartment of Neurology, RWTH Aachen, 52062 Aachen, Germany.
Tugce B BalciDepartment of Paediatrics, The University of Western Ontario, London, ON N6A 5C1, Canada.
Kyle S HoffmanBioinformatic Solutions, Inc, Waterloo, ON N2L 3K8, Canada.
Patrick O'DonoghueDepartment of Biochemistry, The University of Western Ontario, London, ON N6A 5C1, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Huntington's disease (HD) is caused by polyglutamine (polyQ) repeat expansions in the huntingtin gene. HD-causative polyQ alleles lead to protein aggregation, which is a prerequisite for disease. Translation fidelity modifies protein aggregation, and several studies suggest that mutating one or two glutamine (Gln) residues in polyQ reduces aggregation. Thus, we hypothesized that missense suppression of Gln codons with other amino acids will reduce polyQ aggregate formation in cells. In neuroblastoma cells, we assessed tRNA variants that misread Gln codons with serine (tRNA

Indexed as

gene therapyHDHuntington's diseasemissense suppressionmistranslationMT: Non-coding RNAsnon-coding RNApolyglutaminepolyQprotein aggregationtRNA therapeutics

Identifiers

PMID39897579
PMCPMC11787650

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.